Aim: To investigate the potential of preoperative serum total testosterone (TT) in contributing to the definition of separate prostatectomy Gleason score (pGS) groups of the prostate cancer (PCa) population. Materials and Methods: The data of 220 patients operated on for PCa were retrospectively reviewed. No patient had previously received 5α-reductase inhibitor, luteinizing hormone-releasing analogs or testosterone replacement treatment. The patient population was grouped according to the pGS as 6 = 3+3, 7 = 3+4, 7 = 4+3 and 8-10. Eight variables were simultaneously investigated in each group: prostate-specific antigen (PSA), TT, free testosterone, age, percentage of positive prostate biopsy cores (P+), biopsy Gleason score (bGS), overall cancer volume estimated as percentage of prostate volume (V+) and prostate weight (Wi). Univariate analysis of variance (ANOVA), multivariate analysis of variance (MANOVA) and multivariate discriminant analysis (MDA) were the statistical methods used for evaluating the data. Results: There were 89 patients in pGS 6 = 3+3, 84 in pGS 7 = 3+4, 24 in pGS 7 = 4+3 and 23 in pGS 8-10. ANOVA showed that bGS (p < 0.0001), P+ (p < 0.0001), V+ (p < 0.0001), PSA (p = 0.0001), Wi (p = 0.0002) and TT (p = 0.01) were significantly different in the four pGS groups. MANOVA tests showed that only bGS (p < 0.0001), V+ (p = 0.0003), TT (p = 0.001) and, to a lesser extent, PSA (p = 0.06) were the significant variables that individually and independently contributed a significant amount to separation of the four pGS groups of the PCa population. MDA showed that the independent variables ranked as bGS (p < 0.0001), TT (p = 0.001), V+ (p = 0.001) and PSA (p = 0.06). Conclusions: Serum TT is a significant preoperative variable that independently contributes to separating the PCa population into pGS score groups. Pretreatment baseline serum TT levels should be measured and their inclusion in neural networks predicting PCa natural history be considered in the patient population diagnosed with PCa.

Keywords:
Total testosterone, Free testosterone, Prostate-specific antigen, Prostate cancer, Prostatectomy Gleason score
1.
Huggins C, Hodges CV: Studies on prostate cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
3.
Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-195.
4.
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-453.
5.
Olsson M, Ekstrom L, Schulze J, Kjellman A, Akre O, Rane A, Gustafsson O: Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 2010;70:200-205.
6.
Harper ME, Pierrepoint CG, Griffiths K: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-482.
7.
Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002;89:710-713.
8.
Hammond GL, Kontturi M, Maattala P, Puukka M, Vihko R: Serum FSH, LH and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol 1977;7:129-135.
9.
Kumar VL, Wafhwa SN, Kumar V, Farooq A: Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122-128.
10.
Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H: Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol 2000;38:243-249.
11.
Madersbacher S, Shatzl G, Bieglmayer C, Reiter BW, Gassner C, Berger P, Zidek T, Marberger M: Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal axis. Urology 2002;60:869-874.
12.
Fodstad P, Bjoro T, Torlakovic G, Fossa SD: No association of serum gonadal or pituitary hormone with prognostic parameters in stages T1 to T3 pN0M0 prostate cancer. J Urol 2002;168:1188-1192.
13.
Pound CR, Partin AW, Eisenberger M, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
14.
Hull GW, Rabbani F, Abbas FA, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
15.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439.
16.
Cuzik J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P; on behalf of the Transatlantic Prostate Cancer Group: Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006;95:1186-1194.
17.
Monda JM, Myers RP, Bostwick DG, Oesterling JE: The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 1995;46:62-64.
18.
Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Horie S: Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res 2008;28:2487-2492.
19.
Anderson SO, Adami HO, Bergstrom R, Wide B: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population-based case control study. Br J Cancer 1993;68:97-102.
20.
Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-58.
21.
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
22.
Mikkola AK, Aro JL, Rannikko SA, Salo JO: Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostate cancer. FINNPROSTATE Group. Prostate 1999;39:175-181.
23.
Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F: Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 2011;117:5029-5038.
24.
Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK: Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009;73:356-361.
25.
Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K: Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu. Prostate 2010;70:1935-1401.
26.
Hoffman MA, Dewolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-827.
27.
Zhang PL, Rosen S, Veeramachaneni R, Kao J, Dewolf WC, Bubley G: Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-182.
28.
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008;72:1240-1245.
29.
Flemming ID, Cooper JS, Henson DE, Hutte RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JN (ed): American Joint Committee on Cancer Staging Manual, ed 5. Philadelphia, JP Lippincott, 1997, pp 219-222.
30.
Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB: Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010;105:824-829.
31.
Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, Cocco C, Romano M, Artibani W: Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups. Anticancer Res 2012;32:5015-5022.
32.
Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, Combo R, Ferrari M, Castagna G, Rigatti P, Montorsi F: Serum sex steroids depict a nonlinear U shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res 2012;18:3648-3657.
33.
Morgentaler A, Triash AM: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-321.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.